These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

86 related articles for article (PubMed ID: 17389868)

  • 41. A value-based medicine cost-utility analysis of idiopathic epiretinal membrane surgery.
    Gupta OP; Brown GC; Brown MM
    Am J Ophthalmol; 2008 May; 145(5):923-8. PubMed ID: 18329000
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Back to basics: an introduction to economic evaluation.
    Guest JF
    J Wound Care; 2013 Feb; 22(2):100-2. PubMed ID: 23665666
    [No Abstract]   [Full Text] [Related]  

  • 43. Estimating the effects of light rail transit on health care costs.
    Stokes RJ; MacDonald J; Ridgeway G
    Health Place; 2008 Mar; 14(1):45-58. PubMed ID: 17543570
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Economic evaluation of sevelamer in patients with end-stage renal disease.
    Manns B; Klarenbach S; Lee H; Culleton B; Shrive F; Tonelli M
    Nephrol Dial Transplant; 2007 Oct; 22(10):2867-78. PubMed ID: 17595182
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Medicaid-based child restraint system disbursement and education and the vaccines for children program: comparative cost-effectiveness.
    Goldstein JA; Winston FK; Kallan MJ; Branas CC; Schwartz JS
    Ambul Pediatr; 2008; 8(1):58-65. PubMed ID: 18191783
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Money matters: what to look for in an economic analysis.
    Dijksman LM; Poolman RW; Bhandari M; Goeree R; Tarride JE;
    Acta Orthop; 2008 Feb; 79(1):1-11. PubMed ID: 18283565
    [No Abstract]   [Full Text] [Related]  

  • 47. Costs and benefits when treating obesity.
    Sjöström L; Narbro K; Sjöström D
    Int J Obes Relat Metab Disord; 1995 Nov; 19 Suppl 6():S9-12. PubMed ID: 8581116
    [No Abstract]   [Full Text] [Related]  

  • 48. The importance of model inputs and assumptions in conducting health technology assessments of novel drugs.
    Philipson T; MacEwan JP
    J Med Econ; 2017 Oct; 20(10):1107-1109. PubMed ID: 28737052
    [No Abstract]   [Full Text] [Related]  

  • 49. Analytical models in economic evaluation studies.
    Silva EN; Silva MT; Pereira MG
    Epidemiol Serv Saude; 2016; 25(4):855-858. PubMed ID: 27869980
    [No Abstract]   [Full Text] [Related]  

  • 50. Dynamic research, static literature.
    Schriger DL
    Ann Emerg Med; 2010 Oct; 56(4):339-40. PubMed ID: 20868905
    [No Abstract]   [Full Text] [Related]  

  • 51. The desirability and feasibility of economic studies of drugs post-launch.
    Drummond M; Mason A; Towse A
    Eur J Health Econ; 2006 Mar; 7(1):5-6. PubMed ID: 16470374
    [No Abstract]   [Full Text] [Related]  

  • 52. Potential inconsistencies between cost-effectiveness and cost-utility analyses. An upstairs/downstairs socioeconomic distinction.
    Rittenhouse BE
    Int J Technol Assess Health Care; 1995; 11(2):365-76. PubMed ID: 7790177
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Understanding proximal-distal economic projections of the benefits of childhood preventive interventions.
    Slade EP; Becker KD
    Prev Sci; 2014 Dec; 15(6):807-17. PubMed ID: 24337979
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Developing the role of electronic health records in economic evaluation.
    Hazra NC; Rudisill C; Gulliford MC
    Eur J Health Econ; 2019 Nov; 20(8):1117-1121. PubMed ID: 30877401
    [No Abstract]   [Full Text] [Related]  

  • 55. [Possibility of generalizing the results of an economic evaluation].
    Ortega Eslava A
    Farm Hosp; 2003; 27(4):205-9. PubMed ID: 12966449
    [No Abstract]   [Full Text] [Related]  

  • 56. Modeling in economic evaluation: an unavoidable fact of life.
    Halpern MT; McKenna M; Hutton J
    Health Econ; 1998 Dec; 7(8):741-2. PubMed ID: 9890334
    [No Abstract]   [Full Text] [Related]  

  • 57. The long-term effects and economic consequences of treatments for obesity: work in progress.
    Zohrabian A
    Lancet; 2005 Jan 8-14; 365(9454):104-5. PubMed ID: 15639278
    [No Abstract]   [Full Text] [Related]  

  • 58. The skinny on COI analysis.
    Corso P; Grosse S; Finkelstein E
    Obes Res; 2004 Jul; 12(7):1189. PubMed ID: 15292484
    [No Abstract]   [Full Text] [Related]  

  • 59. Shape Up Somerville's return on investment: Multi-group exposure generates net-benefits in a child obesity intervention.
    Coffield E; Nihiser A; Carlson S; Collins J; Cawley J; Lee S; Economos C
    Prev Med Rep; 2019 Dec; 16():100954. PubMed ID: 31463186
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Cost Effectiveness of Childhood Obesity Interventions: Evidence and Methods for CHOICES.
    Gortmaker SL; Long MW; Resch SC; Ward ZJ; Cradock AL; Barrett JL; Wright DR; Sonneville KR; Giles CM; Carter RC; Moodie ML; Sacks G; Swinburn BA; Hsiao A; Vine S; Barendregt J; Vos T; Wang YC
    Am J Prev Med; 2015 Jul; 49(1):102-11. PubMed ID: 26094231
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.